741287-37-6

Basic information

• Product Name: tert-butyl 3-methyl-4-benzyl-1-piperazinecarboxylate
• Synonyms: tert-butyl 3-methyl-4-benzyl-1-piperazinecarboxylate
• CAS NO: 741287-37-6
• Molecular Weight: 290.406
• Mol File: 741287-37-6.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: tert-butyl 3-methyl-4-benzyl-1-piperazinecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 3-methyl-4-benzyl-1-piperazinecarboxylate(741287-37-6)
• EPA Substance Registry System: tert-butyl 3-methyl-4-benzyl-1-piperazinecarboxylate(741287-37-6)

Safety Data

• Hazardous Substances Data: 741287-37-6(Hazardous Substances Data)

Upstream product

• 100-39-0 benzyl bromide 
• 120737-59-9 3-methyl-piperazine-1-carboxylic acid tert-butyl ester 
• 81560-11-4 2-chloro-4-benzyloxy-5-fluoropyrimidine 
• 109-07-9 (RS)-2-methylpiperazine 

Downstream Products

• 741287-35-4 1-benzyl-2-methylpiperazine trifluoroacetate 

Relevant articles and documents

Facile Synthesis of 2-Amino-4-alkoxypyrimidines via Consecutive Nucleophilic Aromatic Substitution (SNAr) Reactions

A transition-metal-free and regioselective synthesis of a series of 2-amino-4-alkoxypyrimidines is described. The SNAr alkoxylation of 2,4-dichloropyrimidines regioselectively provided 2-chloro-4-alkoxypyrimidines, which were subsequently subject to the second SNAr amination with cyclic amines in the presence of triethylamine at high temperature to afford 2-amino-4-alkoxypyrimidines in good overall yield.

SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS

The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.